Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 10
Opinion
Video
CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC
5. Frank Scimeca, PharmD, MBA, BCOP, leads a discussion on sequencing CDK4/6 inhibitors, comparing their side effect profiles, toxicity benefits, and progression-free survival (PFS) advantages. He emphasizes the need for additional biomarkers and clearer guidance from the NCCN to aid in selecting the most appropriate drug for each patient.
Related Videos
Related Content
